Vitamin D Receptor Activators and/or Cinacalcet for Controlling Secondary Hyperparathyroidism


Mineral and Bone Disorder (CKD-MBD), Am J Kidney Dis, 2010;55:773–99.


21. 22. 23.


Komaba H, Fukagawa M, FGF23-parathyroid interaction: implications in chronic kidney disease, Kidney Int, 2010;77:292–8.


Souberbielle JC, Boutten A, Carlier MC, et al., Inter-method variability in PTH measurement: implication for the care of CKD patients, Kidney Int, 2006;70:345–50.


Al-Aly Z, Qazi RA, Gonzalez EA, et al., Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD, Am J Kidney Dis, 2007;50:59–68.


24.


Chandra P, Binongo JN, Ziegler TR, et al., Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study, Endocr Pract, 2008;14:10–7.


25.


Zisman AL, Hristova M, Ho LT, et al., Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease, Am J Nephrol, 2007;27:36–43.


26. 27. 28.


Jones G, Why dialysis patients need combination therapy with both cholecalciferol and a calcitriol analog, Semin Dial, 2010;23:239–43.


Fournier A, Fardellone P, Achard JM, et al., Importance of vitamin D repletion in uraemia, Nephrol Dial Transplant, 1999;14:819–23.


Locatelli F, Cannata-Andia JB, Drueke TB, et al., Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia, Nephrol Dial Transplant, 2002;17:723–31.


29.


Matias PJ, Jorge C, Ferreira C, et al., Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters, Clin J Am Soc Nephrol, 2010;5:905–11.


30.


Dusso AS, Pavlopoulos T, Naumovich L, et al., p21(WAF1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth, Kidney Int, 2001;59:855–65.


31. 32. 33. 34.


Teng M, Wolf M, Ofsthun MN, et al., Activated injectable vitamin D and hemodialysis survival: a historical cohort study, J Am Soc Nephrol, 2005;16:1115–25.


Tentori F, Hunt WC, Stidley CA, et al., Mortality risk among hemodialysis patients receiving different vitamin D analogs, Kidney Int, 2006;70:1858–65.


Teng M, Wolf M, Lowrie E, et al., Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy, N Engl J Med, 2003;349:446–56.


Slatopolsky E, Weerts C, Thielan J, et al., Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients, J Clin Invest, 1984;74:2136–43.


35. 36. 37. 38.


Sprague SM, Moe SM, Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol, Am J Kidney Dis, 1992;19:532–9.


Brown AJ, Dusso AS, Slatopolsky E, Vitamin D analogues for secondary hyperparathyroidism, Nephrol Dial Transplant, 2002;17(Suppl 10):10–9.


Wu-Wong JR, Nakane M, Ma J, et al., Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells, Atherosclerosis, 2006;186:20–8.


Brown AJ, Finch J, Slatopolsky E, Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25- dihydroxyvitamin D(3) on intestinal calcium and phosphate transport, J Lab Clin Med, 2002;139:279–84.


39.


Takahashi F, Finch JL, Denda M, et al., A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content, Am J Kidney Dis, 1997;30:105–12.


40.


Slatopolsky E, Finch J, Ritter C, et al., A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia, Am J Kidney Dis, 1995;26:852–60.


57. 54. 41. 42.


Nakane M, Fey TA, Dixon DB, et al., Differential effects of Vitamin D analogs on bone formation and resorption, J Steroid Biochem Mol Biol, 2006;98:72–7.


Martin KJ, Gonzalez EA, Gellens M, et al., 19-Nor-1-alpha- 25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis, J Am Soc Nephrol, 1998;9:1427–32.


43. 44. 45.


Lindberg J, Martin KJ, Gonzalez EA, et al., A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease, Clin Nephrol, 2001;56:315–23.


Martin KJ, Gonzalez EA, Gellens ME, et al., Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25- dihydroxyvitamin D2, Am J Kidney Dis, 1998;32:S61–6.


Martin KJ, Gonzalez E, Lindberg JS, et al., Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study, Am J Kidney Dis, 2001;38:S57–63.


46.


Ross EA, Tian J, Abboud H, et al., Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis, Am J Nephrol, 2008;28:97–106.


47. 48. 49.


Sprague SM, Llach F, Amdahl M, et al., Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism, Kidney Int, 2003;63:1483–90.


Mittman N, Desiraju B, Meyer KB, et al., Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single- center crossover study, Kidney Int, 2010;78(Supp 117):S33–6.


Shinaberger CS, Kopple JD, Kovesdy CP, et al., Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients, Clin J Am Soc Nephrol, 2008;3:1769–76.


50.


Dobrez DG, Mathes A, Amdahl M, et al., Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings, Nephrol Dial Transplant, 2004;19:1174–81.


51.


Tan AU Jr., Levine BS, Mazess RB, et al., Effective suppression of parathyroid hormone by 1 alpha-hydroxy- vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism, Kidney Int, 1997;51:317–23.


52.


Frazao JM, Elangovan L, Maung HM, et al., Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism, Am J Kidney Dis, 2000;36:550–61.


53.


Maung HM, Elangovan L, Frazao JM, et al., Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison, Am J Kidney Dis, 2001;37:532–43.


Slatopolsky E, Cozzolino M, Finch JL, Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats, Kidney Int, 2002;62:1277–84.


55.


Joist HE, Ahya SN, Giles K, et al., Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients, Clin Nephrol, 2006;65:335–41.


56.


Moriniere P, el Esper N, Viron B, et al., Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1 alpha(OH) vitamin D3, oral CaCO3 and low dialysate calcium, Kidney Int Suppl, 1993;41:S121–4.


Brandi L, Daugaard H, Tvedegaard E, et al., Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis, Am J Nephrol, 1992;12:311–8.


58. 59.


Hamdy NA, Kanis JA, Beneton MN, et al., Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure, BMJ, 1995;310:358–63.


Rix M, Eskildsen P, Olgaard K, Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure, Nephrol Dial Transplant, 2004;19:870–6.


60.


Shoji T, Shinohara K, Kimoto E, et al., Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3


69. 70. 66. 67. 68. 63. 64.


users in a haemodialysis population, Nephrol Dial Transplant, 2004;19:179–84.


61.


Hansen D, Brandi L, Rasmussen K, Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol, BMC Nephrol, 2009;10:28.


62.


Goodman WG, Frazao JM, Goodkin DA, et al., A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism, Kidney Int, 2000;58:436–45.


Nemeth EF, Heaton WH, Miller M, et al.,


Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl, J Pharmacol Exp Ther, 2004;308:627–35.


Levi R, Ben-Dov IZ, Lavi-Moshayoff V, et al., Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1, J Am Soc Nephrol, 2006;17:107–12.


65.


Wada M, Furuya Y, Sakiyama J, et al., The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor, J Clin Invest, 1997;100:2977–83.


Colloton M, Shatzen E, Miller G, et al., Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism, Kidney Int, 2005;67:467–76.


Block GA, Martin KJ, de Francisco AL, et al., Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis, N Engl J Med, 2004;350:1516–25.


Lindberg JS, Culleton B, Wong G, et al., Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study, J Am Soc Nephrol, 2005;16:800–7.


Moe SM, Chertow GM, Coburn JW, et al., Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl, Kidney Int, 2005;67:760–71.


Moe SM, Cunningham J, Bommer J, et al., Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl, Nephrol Dial Transplant, 2005;20:2186–93.


71. 72.


Strippoli GF, Palmer S, Tong A, et al., Meta-analysis of biochemical and patient-level effects of calcimimetic therapy, Am J Kidney Dis, 2006;47:715–26.


Block GA, Zaun D, Smits G, et al., Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients, Kidney Int, 2010;78:578–89.


73.


St Peter WL, Li S, Liu J, et al., Effects of monthly dose and regular dosing of intravenous active vitamin D use on mortality among patients undergoing hemodialysis, Pharmacotherapy, 2009;29:154–64.


74.


Kalantar-Zadeh K, Miller JE, Kovesdy CP, et al., Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D and survival in hemodialysis patients, J Bone Miner Res, 2010;25(12):2448–58.


75.


Urena-Torres P, Raggi P, Chertow GM, et al., The effects of cinacalcet plus low-dose vitamin D on cardiac valve calcification in hemodialysis patients with secondary hyperparathyroidism, NDT Plus, 2010;3:Abstract Su039.


76.


Messa P, Macario F, Yaqoob M, et al., The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism, Clin J Am Soc Nephrol, 2008;3:36–45.


77.


Chertow GM, Blumenthal S, Turner S, et al., Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate, Clin J Am Soc Nephrol, 2006;1:305–12.


78.


Fishbane S, Shapiro WB, Corry DB, et al., Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results, Clin J Am Soc Nephrol, 2008;3:1718–25.


US NEPHROLOGY


37


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100